29.67
Immunocore Holdings Plc Adr stock is traded at $29.67, with a volume of 260.49K.
It is up +0.30% in the last 24 hours and up +1.02% over the past month.
See More
Previous Close:
$29.58
Open:
$29.03
24h Volume:
260.49K
Relative Volume:
0.95
Market Cap:
$1.51B
Revenue:
$345.60M
Net Income/Loss:
$-79.01M
P/E Ratio:
-18.49
EPS:
-1.6045
Net Cash Flow:
$-18.62M
1W Performance:
+0.10%
1M Performance:
+1.02%
6M Performance:
-4.69%
1Y Performance:
-54.35%
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Name
Immunocore Holdings Plc Adr
Sector
Industry
Phone
01235 5430281
Address
90 PARK DRIVE, OXFORDSHIRE
Compare IMCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IMCR
Immunocore Holdings Plc Adr
|
29.67 | 1.51B | 345.60M | -79.01M | -18.62M | -1.6045 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-11-24 | Downgrade | Mizuho | Outperform → Neutral |
Oct-24-24 | Initiated | UBS | Sell |
Oct-07-24 | Downgrade | Guggenheim | Buy → Neutral |
Apr-29-24 | Initiated | Leerink Partners | Outperform |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-31-23 | Initiated | Robert W. Baird | Outperform |
Sep-13-23 | Upgrade | JP Morgan | Neutral → Overweight |
Sep-13-23 | Initiated | Needham | Buy |
Aug-16-23 | Initiated | CapitalOne | Overweight |
Jul-17-23 | Initiated | Canaccord Genuity | Hold |
Mar-31-23 | Initiated | Mizuho | Buy |
Mar-30-23 | Initiated | Guggenheim | Buy |
Mar-24-23 | Initiated | Bryan Garnier | Buy |
Dec-16-22 | Upgrade | Goldman | Neutral → Buy |
Nov-30-22 | Initiated | Barclays | Overweight |
Sep-09-22 | Initiated | Morgan Stanley | Overweight |
Sep-08-22 | Initiated | Ladenburg Thalmann | Buy |
Aug-08-22 | Initiated | Cowen | Outperform |
Aug-02-22 | Initiated | BTIG Research | Buy |
Feb-08-22 | Initiated | H.C. Wainwright | Buy |
Oct-20-21 | Initiated | Oppenheimer | Outperform |
Mar-02-21 | Initiated | Goldman | Neutral |
Mar-02-21 | Initiated | JP Morgan | Overweight |
Mar-02-21 | Initiated | Jefferies | Buy |
View All
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Do investors need to be concerned about Immunocore Holdings plc ADR (IMCR)? - US Post News
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last? - MSN
Immunocore holdings sees $23.99 million in stock purchases by Baker Bros - Investing.com South Africa
Immunocore amends senior notes indenture, files prospectus - Investing.com India
Immunocore amends senior notes indenture, files prospectus By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: biotech firm’s stock outlook amid HIV and cancer drug progress - Investing.com India
BTIG maintains Immunocore stock Buy rating, $91 target - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges - Investing.com
Immunocore stock hits 52-week low at $27.59 amid market challenges By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results By Investing.com - Investing.com South Africa
Immunocore reports promising HIV trial results - Investing.com India
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewswire Inc.
Immunocore at TD Cowen Conference: Strategic Growth and Innovation - Investing.com India
Immunocore at TD Cowen Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa
Earnings call transcript: Immunocore Holdings Q4 2024 misses EPS - Investing.com
Immunocore Holdings earnings missed by $0.23, revenue fell short of estimates - Investing.com
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store? - MSN
A stock that deserves closer examination: Empresa Distribuidora y Comercial Norte S.A. ADR (EDN) - US Post News
I-Mab ADR (IMAB) stock analysis: A simple moving average approach - US Post News
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade - Yahoo Finance
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - Zacks Investment Research
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 - Yahoo Finance
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer - Yahoo Finance
Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term - Yahoo Finance
Disappointing data leads to Immunocore stock downgrade by Morgan Stanley - Investing.com South Africa
Immunocore stock hits 52-week low at $29.23 amid market challenges - Investing.com
Immunocore's SWOT analysis: TCR pioneer's stock faces pivotal year - Investing.com
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy - Yahoo Finance
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study - Yahoo Finance
New Strong Buy Stocks for December 12th - Yahoo Finance
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals - Yahoo Finance
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
SNTI Stock Skyrockets On Initial Data From Phase I Cancer Study - Barchart
Altimmune Stock Up More Than 25% In A Month: Here's Why - Barchart
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Mirum Shares Surge More Than 90% in 6 Months: Here's Why - Yahoo Finance
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
Stack Capital Group announces normal course issuer bid - MSN
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
What will it take for small caps to finally outperform large caps on earnings, performance? - MSN
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
Immunocore Holdings Plc Adr Stock (IMCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):